Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 131, Issue 6, Pages 1565-+Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2013.01.006
Keywords
Birth cohort; double-blind randomized trial; nutritional intervention; cow's milk protein hydrolysate infant formulas; long-term allergy prevention
Categories
Funding
- Federal Ministry for Education, Science, Research and Technology [01 EE 9401-4]
- Federal Ministry for Environment (IUF) [FKZ 20462296]
- Nestle
- Mead Johnson
- Aerocrine
- AstraZeneca
- Novartis
- Deutsche Atemwegsliga
- Gesellschaft fur Padiatrische Allergologie
- Lions Club
- Federal Ministry of the Environment
- German Science Foundation (DFG)
- European Union
- Germany Ministry of Education and Research
- Phadia
- Euroimmune
- MSD
- Danone
- Hipp
Ask authors/readers for more resources
Background: The long-term effect of nutritional intervention with hydrolysate infant formulas on allergic manifestations in high-risk children is uncertain. Objective: We sought to investigate the effect of hydrolysate infant formulas on allergic phenotypes in children with family history of allergies at school age. Methods: We analyzed data from participants of the prospective German Infant Nutritional Intervention study after 10 years of follow-up. At birth, children were randomly assigned to receive, for the first 4 months, one of 4 blinded formulas as breast milk substitute, if necessary: partially hydrolyzed whey formula (pHF-W), extensively hydrolyzed whey formula (eHF-W), extensively hydrolyzed casein formula (eHF-C), or standard cow's milk formula. Outcomes were parent-reported, physician-diagnosed allergic diseases. Log-binomial regression models were used for statistical analysis. Results: The relative risk for the cumulative incidence of any allergic disease in the intention-to-treat analysis (n = 2252) was 0.87 (95% CI, 0.77-0.99) for pHF-W, 0.94 (95% CI, 0.83-1.07) for eHF-W, and 0.83 (95% CI, 0.72-0.95) for eHF-C compared with standard cow's milk formula. The corresponding figures for atopic eczema/dermatits (AD) were 0.82 (95% CI, 0.68-1.00), 0.91 (95% CI, 0.76-1.10), and 0.72 (95% CI, 0.58-0.88), respectively. In the per-protocol analysis (n = 988) effects were stronger. The period prevalence of AD at 7 to 10 years was significantly reduced with eHF-C in this analysis, but there was no preventive effect on asthma or allergic rhinitis. Conclusion: The significant preventive effect on the cumulative incidence of allergic diseases, particularly AD, with pHF-W and eHF-C persisted until 10 years without rebound, whereas eHF-W showed no significant risk reduction. There is insufficient evidence of ongoing preventive activity at 7 to 10 years of age.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available